Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12965960 | 0.85 | MMP1 (0.46) | HCRTR1HCRTR2MMP1MMP2MMP3 | |
| SCHEMBL2831523 | 0.83 | HSD11B1 (0.45) | HCRTR1HCRTR2MMP2HSD11B1CNR1 | |
| SCHEMBL5750486 | 0.80 | L3MBTL1 (0.47) | HCRTR1HCRTR2HSD11B1CNR1 | |
| SCHEMBL15916184 | 0.79 | CNR1 (0.51) | CNR1EPHX2KDM4EALDH1A1 | |
| SCHEMBL15917207 | 0.79 | CNR1 (0.51) | CNR1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2834513 | 0.79 | EPHX2 (0.45) | HCRTR1HCRTR2MMP1MMP2MMP3 | |
| SCHEMBL2840532 | 0.79 | EPHX2 (0.45) | HCRTR1HCRTR2MMP1MMP2MMP3 | |
| SCHEMBL5436955 | 0.76 | SMN1; SMN2 (0.52) | HCRTR1HCRTR2EPHX2NPC1RAB9A | |
| SCHEMBL6500614 | 0.75 | CNR1 (0.52) | CNR1USP2TSHRALDH1A1 | |
| SCHEMBL2704254 | 0.74 | HCRTR1 (0.70) | HCRTR1HCRTR2MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | HCRTR1 2752/4885HCRTR2 722/4885MMP1 4589/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | HCRTR1 4093/4885HCRTR2 1576/4885MMP1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.